Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1992-03-02
1993-12-21
Waddell, Frederick E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514562, 514574, 514706, 514948, 424439, 424440, A61K 31415, A61K 31195, A61K 3119, A61K 31095
Patent
active
052721663
ABSTRACT:
The present invention relates to methods and corresponding agents for lowering plasma Lp(a) levels by the administration of agents that reduce Lp(a) and selectively separate therefrom the apo(a) component and/or prevent Lp(a) formation. Suitable agents include sulfhydryl reducers, such as N-acetylcysteine. The present method and agents may be administered alone or in conjunction with other therapy for the lowering of LDL cholesterol.
REFERENCES:
(Author Unknown) Opportunities in Biology, National Research Counsel (pp. 328-334), (1978).
Armstrong, Victor W., et al., "Isolation, characterization, and uptake in human fibroblasts of an apo(a)-free lipoprotein obtained on reduction of lipoprotein(a)" J. Lipid Res. 26:1314-1323 (1985).
Eldeib, M. M. R., et al., "Reversal of the Biological Activity of Escherichia coli Hear-Stable Enterotoxin by Dusulfide-reducing Agent Infection & Immunity" 51(1):24-30 (Jan., 1986).
Bihari-Varga, M., et al. "Interaction of Lippoprotein Lp(a) and Low Density Lipoprotein with Glycosaminoglycans from Human Aorta". Arteriosclerosis 8(6):851-857 (Nov.-Dec. 1988).
Reynolds, J.(ed) Martindale The Extra Pharmacopoeid (29th ed) (1989). Copies of the pages submitted herewith relate generally to sulfhydryl group reducing agents.
Dictionnaire Vidal (1989) contains a monograph in French pertaining to the commercially available product MUCOMYST. While a translation of this monograph has not been obtained, but a copy of the MUCOMYST product brochure which has been circulated in the United States is enclosed.
Hajjar, K. A., et al., "Lipoprotein (a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis" Nature 339(6222):303-305 (May 25, 1989).
Kostner, Gerhard M., et al., "HMG CoA Reductase Inhibitors Lower LDL Cholesterol Without Reducing Lp(a) Levels" Circulation 80(5):1313-1319 Nov. 1989.
Utermann, G. "The Mysteries of Lipoprotein (a)" Science 246:904-910 (Nov. 17, 1989).
Gavish, D., et al., "Plasma Lp(a) Concentration is Inversely Correlated with the Ratio of Kringle IV/Kringle v Encoding Domains in the Apo(a) Gene" J. Clin Invest. 84:2021-2027 (Dec. 1989).
Gavish, D., et al., "Lipoprotein(a) reduction by N-acetylcysteine" The Lancet 337(8735):203-204 (Jan. 26, 1991).
Stalenhoef, A., "N-acetylcysteine and lipoprotein": The Lancet 337(8739):491 (Feb. 23, 1991).
Hansen, P. R., "Lipoprotein(a) reduction by N-acetylcysteine" The Lancet 337(8742):672-673 (Mar. 16, 1991).
Chemical Abstracts (106: 101184a) 1987.
Chemical Abstracts (107: 114684j) 1987.
Breslow Jan L.
Gavish Dov
The Rockefeller University
Waddell Frederick E.
Weddington K.
LandOfFree
Method for selective reduction of Lp(a) does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for selective reduction of Lp(a), we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for selective reduction of Lp(a) will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-309356